MSAA has been awarded the APEX 2016 Grand Award in the category of Writing for the cover story, “Cognitive Issues with Multiple Sclerosis: Research, Strategies, and Support,” featured in the […]
Read News ArticleAuthor: Multiple Sclerosis Association of America
My MSAA Community Online Forum
Welcome to My MSAA Community, a free online community powered by HealthUnlocked. My MSAA Community is a peer-to-peer online forum (hosted by HealthUnlocked.com) for individuals with MS, their families, and […]
Read News ArticleThe Multiple Sclerosis Association of America Publishes New Resources
The Multiple Sclerosis Association of America (MSAA) is pleased to announce three newly published resources for the multiple sclerosis (MS) community. The new resources are available free-of-charge as both printed […]
Read News ArticleMS Conversations Recognized as Top MS Blog of 2016 by Healthline.com
MSAA’s MS Conversations blog is honored to be named one of 2016’s best multiple sclerosis blogs by Healthline.com. Healthline recently chose 23 blogs that actively work to educate, inspire, and […]
Read News ArticleFDA Approves Zinbryta™ (Daclizumab) for Relapsing Forms of Multiple Sclerosis
Approval and Medication Overview Late on Friday, May 27, 2016, the United States Food and Drug Administration announced the approval of Zinbryta™ (daclizumab) for adults with relapsing forms of multiple […]
Read News ArticleRemaining Adherent
Once a DMT is initiated, evidence suggests that treatment needs to be ongoing for benefits to persist. Non-adherence and gaps in treatment have been associated with an increased rate of […]
Read News ArticleSEARCH-ing for Insurance Coverage
As mentioned earlier in this booklet, healthcare professionals and organizations including MSAA recommend early and continuous treatment of multiple sclerosis through FDA-approved DMTs, if deemed appropriate by one’s doctor. However, […]
Read News ArticleTreatment Chart
This easy-to-follow reference chart shows those medications that have been approved by the FDA and are available for the long-term treatment of relapsing forms of MS. This chart does not […]
Read News ArticleFraming the Discussion
While the issue of treatment adherence continues to gain awareness and momentum, MSAA also recognizes the complexity of the situation. Healthcare providers continue to encourage their patients to become more […]
Read News ArticleThe Changing Landscape
The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration (FDA) in 1993. This forever changed the landscape of how MS could […]
Read News Article